These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17123880)

  • 1. Analyzing the "correct" endpoint.
    Atherton PJ; Novotny PJ; Tan AD
    Curr Probl Cancer; 2006; 30(6):283-97. PubMed ID: 17123880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials.
    Le Cleach L; Chassany O; Levy A; Wolkenstein P; Chosidow O
    Dermatology; 2008; 216(1):46-55. PubMed ID: 18032899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality-of-life outcomes in oncology.
    Siddiqui F; Kachnic LA; Movsas B
    Hematol Oncol Clin North Am; 2006 Feb; 20(1):165-85. PubMed ID: 16580562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
    Baker SG
    Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa.
    Agnihotri P; Telfer M; Butt Z; Jella A; Cella D; Kozma CM; Ahuja M; Riaz S; Akamah J
    J Am Geriatr Soc; 2007 Oct; 55(10):1557-65. PubMed ID: 17697104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
    Wright JR; Ung YC; Julian JA; Pritchard KI; Whelan TJ; Smith C; Szechtman B; Roa W; Mulroy L; Rudinskas L; Gagnon B; Okawara GS; Levine MN
    J Clin Oncol; 2007 Mar; 25(9):1027-32. PubMed ID: 17312332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogate endpoints in randomized cardiovascular clinical trials.
    Domanski M; Pocock S; Bernaud C; Borer J; Geller N; Revkin J; Zannad F
    Fundam Clin Pharmacol; 2011 Aug; 25(4):411-3. PubMed ID: 20698890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical assessment of composite and coprimary endpoints: a complex problem.
    Buzney EA; Kimball AB
    J Am Acad Dermatol; 2008 Nov; 59(5):890-6. PubMed ID: 19119103
    [No Abstract]   [Full Text] [Related]  

  • 10. Dealing with multiple endpoints.
    Dueck A; Novotny PJ
    Curr Probl Cancer; 2006; 30(6):298-306. PubMed ID: 17123881
    [No Abstract]   [Full Text] [Related]  

  • 11. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.
    Sridhara R; Mandrekar SJ; Dodd LE
    Clin Cancer Res; 2013 May; 19(10):2613-20. PubMed ID: 23669421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing multiplicity issues of a composite endpoint and its components in clinical trials.
    Huque MF; Alosh M; Bhore R
    J Biopharm Stat; 2011 Jul; 21(4):610-34. PubMed ID: 21516560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing homogeneity of two zero-inflated Poisson populations.
    Tse SK; Chow SC; Lu Q; Cosmatos D
    Biom J; 2009 Feb; 51(1):159-70. PubMed ID: 19219907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the measure of a new drug: is survival the only thing that matters?
    Sargent DJ; Hayes DF
    J Clin Oncol; 2008 Apr; 26(12):1922-3. PubMed ID: 18421044
    [No Abstract]   [Full Text] [Related]  

  • 16. The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer.
    Fan HG; Park A; Xu W; Yi QL; Braganza S; Chang J; Couture F; Tannock IF
    Psychooncology; 2009 Feb; 18(2):156-61. PubMed ID: 18561284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 18. Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials.
    Eickhoff JC
    Stat Med; 2008 Apr; 27(9):1387-402. PubMed ID: 18219702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint.
    Nixon RM; Duffy SW; Fender GR
    BMC Med Res Methodol; 2003 Sep; 3():17. PubMed ID: 14507420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.